Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 10/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19152687 | 0.77 | PDE3B (0.46) | PDE3BPDE3AMAPKAPK2 | |
| SCHEMBL29320119 | 0.77 | TYRO3 (0.50) | PDE3BPDE3AKDM4ECMA1 | |
| SCHEMBL338446 | 0.76 | PDE3B (0.49) | PDE3BPDE3ACMA1 | |
| SCHEMBL18238489 | 0.73 | PDE3B (0.47) | PDE3BPDE3AALDH1A1LMNAMAPKAPK2 | |
| SCHEMBL19131092 | 0.73 | PDE3B (0.41) | PDE3BPDE3A | |
| SCHEMBL8664696 | 0.67 | LIMK1 (0.39) | PDE3BPDE3AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31465446 | 0.67 | TYRO3 (0.61) | PDE3BPDE3AALDH1A1RPS6KA3 | |
| SCHEMBL1983844 | 0.65 | ALDH1A1 (0.43) | PDE3BPDE3AALDH1A1KDM4ELMNA | |
| SCHEMBL12232628 | 0.65 | PDE3B (0.54) | PDE3BPDE3AALDH1A1 | |
| SCHEMBL17904270 | 0.64 | RPS6KA3 (0.37) | PDE3BPDE3AALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076132-B1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-BETA -D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | ANADYS PHARMACEUTICALS INC (US) | 2012-07-11 | — | — | EP | claimed |
| US-7928085-B2 | P-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazole[4,5-d]pyrimidine-2-one and methods for preparation | ANADYS PHARMACEUTICALS, INC. (US) | 2011-04-19 | — | — | US | claimed |
| US-7781581-B2 | Process for the preparation of 5-amino-3H-thiazolo[4,5-d]pyrimidin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | claimed |
| EP-1973920-B1 | PROCESS FOR THE PREPARATION OF 5-AMINO-3H-THIAZOLO [4,5-D] PYRIMIDIN-2-ONE | ANADYS PHARMACEUTICALS INC (US) | 2010-07-21 | — | — | EP | claimed |
| US-20090197826-A1 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | claimed |
| EP-2076132-A1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-BETA -D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | Anadys Pharmaceuticals, Inc. (US) | 2009-07-08 | — | — | EP | claimed |
| WO-2008140549-A1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| US-20070117979-A1 | Novel process for the preparation of 5-amino-3H-thiazolo[4,5-d]pyrimidin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | claimed |
| EP-3568400-B1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025032082-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-02-13 | — | — | WO | disclosed |
| EP-3695837-B1 | A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR FOR TREATING HEPATITIS B | HOFFMANN LA ROCHE (CH) | 2024-11-20 | — | — | EP | disclosed |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4319758-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | Forma Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20070117979-A1 | Novel process for the preparation of 5-amino-3H-thiazolo[4,5-d]pyrimidin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117979-A1 | Novel process for the preparation of 5-amino-3H-thiazolo[4,5-d]pyrimidin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117979-A1 | Novel process for the preparation of 5-amino-3H-thiazolo[4,5-d]pyrimidin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006066080-A1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20050070556-A1 | 3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117979-A1 | Novel process for the preparation of 5-amino-3H-thiazolo[4,5-d]pyrimidin-2-one | TYMS, TYMP, TPMT | PDE3B 1245/4885PDE3A 1503/4885ALDH1A1 824/4885 |
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | HAVCR2, IFNG, TPMT | PDE3B 709/4885PDE3A 725/4885ALDH1A1 273/4885 |
| US-20090197826-A1 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation | DPYD, APRT, TYMS | PDE3B 4825/4885PDE3A 4588/4885ALDH1A1 251/4885 |
| US-20050070556-A1 | 3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof | ENTPD5, DPYD, TYMP | PDE3B 864/4885PDE3A 1051/4885ALDH1A1 1278/4885 |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | USP1, USP2, USP3 | PDE3B 2997/4885PDE3A 2604/4885ALDH1A1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.